This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CML | |
|---|---|
| Name | Chronic myelogenous leukemia |
| Field | Hematology, Oncology |
| Symptoms | Fatigue, weight loss, splenomegaly |
| Complications | Blast crisis, infection, bleeding |
| Onset | Middle age |
| Causes | BCR-ABL1 fusion gene |
| Risks | Ionizing radiation exposure, male sex |
| Diagnosis | Peripheral blood smear, bone marrow biopsy, PCR for BCR-ABL1 |
| Treatment | Tyrosine kinase inhibitors, allogeneic stem cell transplant |
| Frequency | 1–2 per 100,000 per year |
CML Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by uncontrolled proliferation of myeloid lineage cells. It is defined molecularly by the BCR-ABL1 fusion oncogene, typically presenting in a chronic phase before progressing to accelerated or blast phases if untreated. Management has been transformed by targeted therapy, altering natural history and survival.
CML was first recognized in clinical descriptions by John Hughes Bennett and pathologic correlations by Donné and later cytogenetic linkage by Peter Nowell and David Hungerford. Landmark discoveries include the Philadelphia chromosome observed by Nowell and Hungerford and the molecular identification of the BCR-ABL1 fusion, which informed targeted drug development by teams at University of California, San Francisco and pharmaceutical groups such as Novartis and Bristol-Myers Squibb. The disease sits within classifications by the World Health Organization and is managed according to guidelines from organizations like the European Society for Medical Oncology and the National Comprehensive Cancer Network.
Patients often present with nonspecific constitutional symptoms documented in case series from centers like Mayo Clinic and Memorial Sloan Kettering Cancer Center, including fatigue, night sweats, and weight loss. Physical findings described in classic textbooks from Oxford University Press and reports from Johns Hopkins Hospital include splenomegaly and hepatomegaly owing to extramedullary hematopoiesis. Laboratory abnormalities noted in cohorts from MD Anderson Cancer Center include leukocytosis with left-shifted myeloid series, basophilia, and thrombocytosis. Complications enumerated in reviews from Lancet and New England Journal of Medicine include progression to blast crisis with features resembling acute myeloid leukemia or acute lymphoblastic leukemia, bleeding diatheses, and increased infection risk.
The defining lesion is the reciprocal translocation t(9;22)(q34;q11), historically linked to work at Fox Chase Cancer Center and molecularly elucidated in research from Cold Spring Harbor Laboratory. This translocation generates the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase, activating downstream pathways studied in labs at Harvard Medical School, Stanford University, and MIT. Key signaling cascades involved include RAS/MAPK, PI3K/AKT, and STAT pathways, mechanisms also investigated in studies led by Tony Hunter and Phil Green. Additional cytogenetic abnormalities described in case series from Fred Hutchinson Cancer Center and Royal Marsden Hospital—such as trisomy 8 or isochromosome 17q—associate with disease progression. Germline and environmental risk factors, including ionizing radiation exposure documented after Hiroshima and Nagasaki and therapeutic radiation scenarios from oncology registries at University College London Hospitals, influence incidence.
Diagnostic criteria incorporate hematologic, cytogenetic, and molecular assays standardized by groups like World Health Organization and laboratory protocols developed at European LeukemiaNet. Initial workup draws on techniques from pathology departments at Mayo Clinic: complete blood count, peripheral smear revealing leukocytosis and myelocyte bulge, and bone marrow aspiration showing granulocytic hyperplasia. Cytogenetic karyotyping and fluorescence in situ hybridization—methods advanced at Cold Spring Harbor Laboratory—detect the Philadelphia chromosome. Reverse transcription polymerase chain reaction for BCR-ABL1 transcripts, with quantitation on the International Scale set by collaborations among European LeukemiaNet, provides molecular monitoring critical for treatment response assessment cited in consensus statements from American Society of Hematology.
The therapeutic paradigm was revolutionized by imatinib, developed through collaborations involving Novartis and academic groups at Dana-Farber Cancer Institute, and subsequent second- and third-generation tyrosine kinase inhibitors (TKIs) from companies such as Boehringer Ingelheim and Pfizer. First-line management follows randomized trials reported by networks including European Organization for Research and Treatment of Cancer and Intergroup studies: TKIs are initiated based on risk scores like Sokal and Hasford developed in cohorts at University of Queensland and University of Heidelberg. Monitoring for molecular response uses standardized PCR assays from reference labs at Molecular Diagnostics Laboratories Network. For TKI resistance or intolerance, options include dose modification, switching TKIs, allogeneic hematopoietic stem cell transplantation performed at centers such as Fred Hutchinson Cancer Center, and investigational agents evaluated at institutions like National Institutes of Health. Supportive care draws on transfusion services at hospitals like Guy’s Hospital and infection prophylaxis protocols from Centers for Disease Control and Prevention.
Population studies from registries maintained by SEER Program and national cancer institutes in United Kingdom and Australia estimate incidence at 1–2 per 100,000 per year, with median age at diagnosis in the sixth decade reported in series from Swedish Cancer Registry. Survival has improved markedly since TKI introduction, with long-term outcomes reported by European LeukemiaNet and International CML Foundation showing near-normal life expectancy for many patients. Prognostic scoring systems—Sokal, Hasford, and EUTOS—originated from multicenter datasets including MD Anderson and Royal Melbourne Hospital and stratify risk. Disparities in access and outcomes are documented in analyses by World Health Organization and global health NGOs.
Ongoing research themes include efforts to achieve treatment-free remission explored in trials run by European LeukemiaNet and Stop Imatinib Trial investigators, novel TKIs developed by pharmaceutical consortia like Array BioPharma and immunotherapeutic approaches studied at Memorial Sloan Kettering Cancer Center. Basic science inquiries into leukemic stem cell biology are pursued at Cold Spring Harbor Laboratory and Broad Institute, while gene-editing strategies leveraging CRISPR work from University of California, Berkeley and Broad Institute are in preclinical stages. Collaborative networks such as International CML Foundation and funding bodies like National Cancer Institute coordinate multicenter trials to refine discontinuation criteria, overcome resistance mechanisms, and develop curative strategies.